NO20081550L - Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske - Google Patents

Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske

Info

Publication number
NO20081550L
NO20081550L NO20081550A NO20081550A NO20081550L NO 20081550 L NO20081550 L NO 20081550L NO 20081550 A NO20081550 A NO 20081550A NO 20081550 A NO20081550 A NO 20081550A NO 20081550 L NO20081550 L NO 20081550L
Authority
NO
Norway
Prior art keywords
reduction
tears
preventive
therapeutic agent
present
Prior art date
Application number
NO20081550A
Other languages
English (en)
Norwegian (no)
Inventor
Mamoru Kobayashi
Tetsuya Asari
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of NO20081550L publication Critical patent/NO20081550L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20081550A 2005-08-29 2008-03-31 Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske NO20081550L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005247563 2005-08-29
PCT/JP2006/316836 WO2007026630A1 (ja) 2005-08-29 2006-08-28 涙液の減少に伴う疾患の予防又は治療剤

Publications (1)

Publication Number Publication Date
NO20081550L true NO20081550L (no) 2008-05-28

Family

ID=37808722

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081550A NO20081550L (no) 2005-08-29 2008-03-31 Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske

Country Status (14)

Country Link
US (1) US20100197788A9 (zh)
EP (1) EP1938837A4 (zh)
JP (1) JPWO2007026630A1 (zh)
KR (1) KR20080038412A (zh)
CN (1) CN101252952A (zh)
AU (1) AU2006285963A1 (zh)
BR (1) BRPI0615339A2 (zh)
CA (1) CA2619445A1 (zh)
IL (1) IL189620A0 (zh)
NO (1) NO20081550L (zh)
RU (1) RU2008112176A (zh)
TW (1) TW200744635A (zh)
WO (1) WO2007026630A1 (zh)
ZA (1) ZA200801858B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1955707A4 (en) * 2005-11-28 2010-09-01 Kissei Pharmaceutical PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROGENIC PAIN
TW200806285A (en) * 2006-03-30 2008-02-01 Santen Pharmaceutical Co Ltd Therapeutic agent for keratoconjunctive problem
WO2008102790A1 (ja) * 2007-02-21 2008-08-28 Kissei Pharmaceutical Co., Ltd. 涙液の減少に伴う疾患の予防または治療用医薬組成物
JPWO2010041568A1 (ja) 2008-10-09 2012-03-08 旭化成ファーマ株式会社 インダゾール誘導体
KR20110050734A (ko) 2008-10-09 2011-05-16 아사히 가세이 파마 가부시키가이샤 인다졸 화합물
US20100222404A1 (en) * 2008-11-04 2010-09-02 Asahi Kasei Pharma Corporation Indazole derivative dihydrochloride
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US20110294897A1 (en) * 2009-12-02 2011-12-01 Bridge Pharma, Inc. Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
GB201612165D0 (en) * 2016-07-13 2016-08-24 Atrogi Ab Combinations for the treatment of type 2 diabetes
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5768684A (en) * 1994-03-04 1998-06-16 Motorola, Inc. Method and apparatus for bi-directional power control in a digital communication system
KR980007105A (ko) * 1996-06-28 1998-03-30 김광호 이동국 송신전력 제어방법
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
US6064659A (en) * 1998-07-10 2000-05-16 Motorola, Inc. Method and system for allocating transmit power to subscriber units in a wireless communications system
JP3471662B2 (ja) * 1998-08-28 2003-12-02 松下電器産業株式会社 送受信装置及びその送信電力制御方法
US6311070B1 (en) * 1999-03-22 2001-10-30 Nortel Networks Limited Variable step size for power control bits to protect against power overshoot
EP1045529B1 (en) * 1999-04-12 2006-11-29 Alcatel A method for improving performances of a mobile radiocommunication system using a power control algorithm
WO2001041806A1 (fr) 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Compositions ophtalmiques
KR100324425B1 (ko) * 1999-12-29 2002-02-27 박종섭 Ｃｄｍａ 시스템에서의 기지국 및 이동국간 순방향/역방향링크 전력제어 방법
JP2001268637A (ja) * 2000-03-15 2001-09-28 Nec Corp 移動機及び基地局並びにそれ等を用いた移動通信システム
CA2313290A1 (en) * 2000-06-30 2001-12-30 Frank Van Heeswyk Adaptive rate power control cdma system
US6856644B1 (en) * 2000-10-31 2005-02-15 Motorola, Inc. Method and apparatus for forward link power control bit generation in a spread-spectrum communication system
JP3577021B2 (ja) * 2001-09-12 2004-10-13 埼玉日本電気株式会社 移動局および移動局における電界状態判定方法
WO2004072016A1 (ja) * 2003-02-14 2004-08-26 Kissei Pharmaceutical Co., Ltd. アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途

Also Published As

Publication number Publication date
IL189620A0 (en) 2008-06-05
CN101252952A (zh) 2008-08-27
ZA200801858B (en) 2009-07-29
US20100197788A9 (en) 2010-08-05
KR20080038412A (ko) 2008-05-06
US20080306160A1 (en) 2008-12-11
JPWO2007026630A1 (ja) 2009-03-05
TW200744635A (en) 2007-12-16
AU2006285963A1 (en) 2007-03-08
BRPI0615339A2 (pt) 2011-05-17
CA2619445A1 (en) 2007-03-08
WO2007026630A1 (ja) 2007-03-08
EP1938837A1 (en) 2008-07-02
RU2008112176A (ru) 2009-10-10
EP1938837A4 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
NO20081550L (no) Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske
DK2170857T3 (da) 3',4',5-trimethoxyflavonderivater som stimulerende middel ved slimafsondring, tilsvarende fremgangsmåde og farmaceutisk præparat, der indeholder disse
Stevens et al. Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial
WO2008137863A3 (en) Methods and devices for measuring tear film and diagnosing tear disorders
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
JP5616620B2 (ja) 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物
UY30060A1 (es) Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos
ATE417607T1 (de) Sphingolipide gegen krankhafte prozesse in lipid rafts
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
WO2008005534A3 (en) Orally dissolving formulations of memantine
BRPI0710085B8 (pt) composições oftálmicas e seus kits
DK1884234T3 (da) Profylaktisk eller terapeutisk middel til korneale og konjunktivale lidelser
BRPI0409622A (pt) derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer
WO2008059501A8 (en) Use of lipid conjugates in the treatment of diseases or disorders of the eye
BR112013005438A2 (pt) "agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo."
MX2008015976A (es) Tratamiento topico para enfermedades de superficie ocular.
EP1915998A8 (en) Prophylactic or therapeutic agent for corneal/conjunctival disease
Aksoy et al. Central corneal thickness and its relationship to Parkinson’s disease severity
CN103068364A (zh) 不含防腐剂的比马前列素和噻吗洛尔溶液
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
DE602006008186D1 (de) Neues imprägnierverfahren einer textiloberfläche
CY1111384T1 (el) Διαμορφωση των επιπεδων εκφρασης toy trpv
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX2009004792A (es) Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application